National Commission on AIDS
Met July 11 to discuss a draft of a report to be submitted to Congress Sept. 19 that will make recommendations on various AIDS issues. The panel discussed criteria for orphan drug status, suggesting that a drug grossing over $ 200 mil. per year should lose its orphan status. The committee later decided to withhold the specific numeric figure from the draft report while further considering the proposal. Public distribution of any future AIDS vaccine was also discussed; it was suggested that such a vaccine should be administered to the public without charge, "like a Salk vaccine." The commission will meet again Aug. 7 to discuss final changes to the draft.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth